Overview

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Radiation therapy to the brain may be effective in preventing brain metastases in patients with advanced non-small cell lung cancer. It is not yet known whether radiation therapy is more effective than observation in patients with advanced non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to the brain to see how well it works compared with observation in preventing brain metastases in patients with advanced non-small cell lung cancer

Phase:

Phase 3

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

Erlotinib Hydrochloride
Gefitinib